PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics

Reuters

05/14

PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href="https://laohu8.com/S/TCRT">Alaunos Therapeutics</a>

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535302543"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535302543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535302543?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535302543","market":"us","top_or_hot":-1,"title":"PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Capital LLC, a subsidiary of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-14 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Capital LLC, a subsidiary of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAB","symbol_name":"PMGC Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3Z3jdl:1","article_id":"2535302543","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535302543","pubTimestamp":1747224057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. , has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. . This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELAB":"PMGC Holdings","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4183":"个人用品","TCRT":"Alaunos Therapeutics","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"PMGC Capital LLC将提交附表13D，收购Alaunos Therapeutics 5.09%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":0.9,"NDAQ":0.9,"TCRT":0.9},"content_text":"PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics\n\n\n        PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}